Ordering Recommendation

May be used as a marker of severe combined immunodeficiency (SCID); lack of adenosine deaminase (ADA) allows deoxyadenosine to accumulate and kill lymphocytes.

Mnemonic
ADA
Methodology

Kinetic Spectrophotometry

Performed

Sun, Tue, Thu

Reported

1-4 days

New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation
Collect

Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).

Specimen Preparation

Do not freeze. Transport 1 mL whole blood.

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Hemolyzed specimens.

Remarks
Stability

Ambient: 15 days; Refrigerated: 15 days; Frozen: Unacceptable

Reference Interval

Effective August 20, 2012

400-900 mU/g Hb

Interpretive Data

Adenosine Deaminase (ADA) deficiency is an autosomal recessive disorder of purine metabolism primarily affecting lymphocyte development, viability, and function. Affected individuals have less than 1 percent of normal ADA catalytic activity in red cell hemolysates. ADA deficiency is the cause of 20-30 percent of SCID cases. If the patient has been recently transfused, ADA deficiency may be masked; interpret results with caution. Heterozygotes cannot be identified by this test.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note
Hotline History
N/A
CPT Codes

84311

Components
Component Test Code* Component Chart Name LOINC
0083001 Adenosine Deaminase RBC 47549-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • ADA
Adenosine Deaminase, RBC